The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
Vertex’s new drug Journavx (suzetrigine) has been hailed as a scientific breakthrough because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx ...
The FDA on Thursday approved Vertex Pharmaceuticals' Journavx to treat moderate to severe acute pain in adults. Acute pain is short-term pain often caused by surgery, accident or injury.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results